

25 November 2025

Further Drawdown of Tranche 1 of the Redeemable Convertible Notes

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX: OSX or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – as announced on 24 December 2024, entered into a subscription agreement (**Subscription Agreement**) with Advance Opportunities Fund and Advance Opportunities Fund I (**Subscribers**).

In accordance with the terms of the Subscription Agreement, the Company intends to issue the Subscribers 4.0% redeemable convertible notes with an aggregate nominal value of up to A\$20,000,000 comprising four equal tranches of a nominal value of A\$5,000,000 each (collectively, the “**Notes**” and individually, “**T1**”, “**T2**”, “**T3**” and “**T4**”). Each of T1, T2, T3 and T4 shall comprise of 20 equal sub-tranches of A\$250,000 (each “**ST01**” to “**ST20**”).

As announced on:

- (a) 14 February 2025, the conditions precedent as set forth in the Subscription Agreement in respect of T1 have been fulfilled, and the Subscribers subscribed for 8 equal sub-tranches (being ST01 to ST08) of T1 Notes, in an aggregate nominal amount of A\$2,000,000.
- (b) 7 April 2025, the Subscribers subscribed for a further 4 equal sub-tranches (being ST09 to ST12) of T1 Convertible Notes, for an aggregate nominal amount of A\$1,000,000.
- (c) 16 May 2025, the Subscribers subscribed for a further 2 equal sub-tranches (being ST13 and ST14) of T1 Convertible Notes, for an aggregate nominal amount of A\$500,000.
- (d) 23 May 2025, the Subscribers subscribed for a further 2 equal sub-tranches (being ST15 and ST16) of T1 Convertible Notes, for an aggregate nominal amount of A\$500,000.

The Company confirms that the Subscribers have subscribed for a further sub-tranche (being ST17) of T1 Notes, in an aggregate nominal amount of A\$250,000.

The funds raised from the issue of the Notes will be used for the ordinary course of business and/or future developments, projects and investments as and when business opportunities arise.

ENDS

This announcement dated 25 November 2025 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr. Yujing Lim
CEO & CTO
Osteopore Limited
E: lim_yujing@osteopore.com

Mark Leong
Executive Chairman
Osteopore Limited
E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Limited is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The Company seeks to commercialise products that stimulate natural bone healing across multiple segments.

Osteopore creates patented scaffolds using 3D-printed biomimetic and bioresorbable materials to guide and nurture bone-forming cells. Through our proprietary manufacturing process – which uses a naturally dissolving polymer – our patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Some of the statements appearing in this announcement may be in the nature of forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing

For personal use only



exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward- looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by a number of factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement.

This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.



For personal use only